Literature DB >> 98826

Normal values for free light chains in serum different age groups.

K Sølling.   

Abstract

The concentration of free light chains from the immunoglobulins was measured in twelve paired sera from mothers and newborns and from 149 sera from normal individuals in various age groups. Variations in concentration during life are correlated to the variations in the concentration of 'regular' immunoglobulins. A concentration of light chains in cord blood of 35% of mean normal adult level (MNA) together with a rapid passage of light chains across the placenta is interpreted as indicating catabolization of maternal light chains in the fetus. This is further supported by the finding of a lower concentration of light chains in maternal serum than in normal adult serum. The investigation shows that the concentration of light chains falls rapidly from 35 to 24% of MNA during the first few days of life. From the first week of life the concentration of light chains increases and low normal adult values are attained by one year of age. Except for difference in concentration, the elution pattern for light chains from Sephadex G-100 columns was similar for normal, adult and cord blood. The relationship between kappa and lambda chains--the K/L ratio--is 1.2 for normal and maternal serum and 1.0 for cord serum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 98826

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

1.  Proteolytic components of serum IgG preparations.

Authors:  L Li; R Kalaga; S Paul
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis.

Authors:  Tom Groot Kormelink; Annie Pardo; Karen Knipping; Ivette Buendía-Roldán; Carolina García-de-Alba; Bart R Blokhuis; Moises Selman; Frank A Redegeld
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

3.  Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Authors:  Nadine Norton; Nicholas Fox; Christie-Ann McCarl; Kathleen S Tenner; Karla Ballman; Courtney L Erskine; Brian M Necela; Donald Northfelt; Winston W Tan; Carmen Calfa; Mark Pegram; Gerardo Colon-Otero; Edith A Perez; Raphael Clynes; Keith L Knutson
Journal:  Breast Cancer Res       Date:  2018-06-14       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.